HashKey and BugsCoin Strengthen Ties Through An Ecosystem Partnership
HAMILTON, Bermuda, Feb. 18, 2025 /PRNewswire/ — HashKey has announced a partnership with BugsCoin (BGSC), the reward token used on the global mock trading platform, ANTTALK GLOBAL. As part of this partnership, both entities will explore potential integration with HashKey Chain, leveraging its secure and scalable blockchain technology to enhance the user experience for mock trading competitions. The partnership also aligns with HashKey’s broader ecosystem strategy, aiming to drive innovation and adoption within the crypto space.
BugsCoin (BGSC) is a reward-based token used on the ANTTALK GLOBAL platform that provides users with rewards through virtual trading activities while simultaneously offering opportunities for practical experience and learning in cryptocurrency trading. This allows users to experience a simulated trading environment and gain a deeper understanding of the cryptocurrency market. Currently, BGSC has already been listed on Bitget, Gate.io and Mexc.
This partnership marks a significant step toward fostering greater financial literacy, trading proficiency, and blockchain adoption globally. Through this collaboration, HashKey Chain and ANTTALK GLOBAL aim to bring more innovation to the trading ecosystem while providing a dynamic and rewarding experience for users worldwide.
Disclaimer: This material is for general information purposes only. It does not constitute, nor should be interpreted as, any form of solicitation, offer or recommendation of any product or service. It does not constitute investment, tax or legal advice. In no event should any news release be considered as recommendation of a particular type of digital asset. Investing and trading digital assets involve risks. Certain services, features, and campaigns of HashKey may not be available in your jurisdiction.
ข่าวที่เกี่ยวข้อง
- NAVEE MENA 2026 Istanbul Partner Summit: Advancing an Integrated Land-Water-Sky Mobility Ecosystem
- โครงสร้างพื้นฐานดิจิทัลชั้นนำเพื่อขับเคลื่อนระบบรางอัจฉริยะ
- SWJTU lays tracks for unified rail future
- Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
